Status:
COMPLETED
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
Lead Sponsor:
Solvay Pharmaceuticals
Collaborating Sponsors:
H. Lundbeck A/S
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.
Eligibility Criteria
Inclusion
- Diagnosis of Schizophrenia or Schizoaffective disorder
- 18-55 years
Exclusion
- Subjects who are acutely psychotic
- Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia
- Subjects at significant risk of suicide
- Subjects with a seizure disorder
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00141479
Start Date
May 1 2005
End Date
November 1 2006
Last Update
January 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 1
Wichita, Kansas, United States